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Introduction: Upregulation of PI3K/Akt/mTOR signalling in endocrine-resistant breast cancer (BC) has identified
mTOR as an attractive target alongside anti-hormones to control resistance. RAD001 (everolimus/Afinitor®), an allosteric
mTOR inhibitor, is proving valuable in this setting; however, some patients are inherently refractory or relapse during
treatment requiring alternative strategies. Here we evaluate the potential for novel dual mTORC1/2 mTOR kinase
inhibitors, exemplified by AZD8055, by comparison with RAD001 in ER + endocrine resistant BC cells.
Methods: In vitro models of tamoxifen (TamR) or oestrogen deprivation resistance (MCF7-X) were treated with RAD001
or AZD8055 alone or combined with anti-hormone fulvestrant. Endpoints included growth, cell proliferation (Ki67),
viability and migration, with PI3K/AKT/mTOR signalling impact monitored by Western blotting. Potential ER cross-talk
was investigated by immunocytochemistry and RT-PCR.
Results: RAD001 was a poor growth inhibitor of MCF7-derived TamR and MCF7-X cells (IC50 ≥1 μM), rapidly inhibiting
mTORC1 but not mTORC2/AKT signalling. In contrast AZD8055, which rapidly inhibited both mTORC1 and mTORC2/AKT
activity, was a highly effective (P <0.001) growth inhibitor of TamR (IC50 18 nM) and MCF7-X (IC50 24 nM), and of a further
T47D-derived tamoxifen resistant model T47D-tamR (IC50 19 nM). AZD8055 significantly (P <0.05) inhibited resistant cell
proliferation, increased cell death and reduced migration. Furthermore, dual treatment of TamR or MCF7-X cells with
AZD8055 plus fulvestrant provided superior control of resistant growth versus either agent alone (P <0.05). Co-treating
with AZD8055 alongside tamoxifen (P <0.01) or oestrogen deprivation (P <0.05) also effectively inhibited endocrine
responsive MCF-7 cells. Although AZD8055 inhibited oestrogen receptor (ER) ser167 phosphorylation in TamR and
MCF7-X, it had no effect on ER ser118 activity or expression of several ER-regulated genes, suggesting the mTOR kinase
inhibitor impact was largely ER-independent. The capacity of AZD8055 for ER-independent activity was further evidenced
by growth inhibition (IC5018 and 20 nM) of two acquired fulvestrant resistant models lacking ER.
Conclusions: This is the first report demonstrating dual mTORC1/2 mTOR kinase inhibitors have potential to control
acquired endocrine resistant BC, even under conditions where everolimus fails. Such inhibitors may prove of particular
benefit when used alongside anti-hormonal treatment as second-line therapy in endocrine resistant disease, and also
potentially alongside anti-hormones during the earlier endocrine responsive phase to hinder development of resistance.* Correspondence: gee@cardiff.ac.uk
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Growth of the majority of breast cancers is stimulated by
oestrogen and this oestrogen receptor (ER) signalling can
be successfully blocked by anti-hormonal treatments, in-
cluding aromatase inhibitors or the oestrogen receptor
antagonists, tamoxifen or fulvestrant. Anti-hormone treat-
ment is effective in a high proportion of initially respon-
sive patients but subsequently a significant number
acquire resistance with resulting poorer survival rates [1].
Consequently, there is an urgent need for treatments for
breast cancer that improve responses to prevent or delay
endocrine resistance. In an attempt to overcome endo-
crine resistance, studies have focussed on developing novel
agents that can reverse resistance by targeting growth fac-
tor signalling pathways. Endocrine resistant cells can be
highly dependent on the use of activated growth factor
signalling pathways including epidermal growth factor re-
ceptor (EGFR) and human epidermal growth factor
receptor-2 (HER2) [2]. The phosphatidylinositol 3-kinase
(PI3K)/Akt/mammalian target of rapamycin (mTOR) sig-
nalling network is also often prominent in endocrine re-
sistant breast cancer, extending to tamoxifen resistant and
oestrogen deprivation resistant MCF-7-derived cell lines
[3-5]. In patients with invasive breast cancer, increased ac-
tivation of this pathway is associated with poor prognosis
[6] and, thus, mTOR has recently been recognised as an
important drug target for breast cancer therapy [7].
mTOR is a highly conserved serine/threonine protein
kinase that belongs to the PI3K- related family and
serves as a central regulator of cell metabolism, growth,
proliferation and survival [8]. Extensive knowledge about
the function of this protein has come from the experi-
mental use of the natural bacterial antibiotic rapamycin,
which inhibits the activity of mTOR. mTOR consists of
two separate multi-protein complexes, mTORC1 and
mTORC2, that are both activated by growth factor sti-
mulation. The mTORC1 complex is rapamycin sensitive;
rapamycin binds the FK506-binding protein (FKBP-12)
which binds to and causes allosteric inhibition of the sig-
nalling complex mTORC1 [9] which contains mTOR,
the regulatory associated protein (RAPTOR), mLST8,
PRAS40 and DEPTOR proteins. mTORC1 positively
regulates protein translation and synthesis via its main
substrates, p70 ribosomal S6 kinase (p70S6K) and the
eukaryotic initiation factor 4E binding protein-1 (4E-BP1).
Upon phosphorylation, 4E-BP1 dissociates from the
mRNA cap-binding protein eIF4E and allows it to
interact with eIF4G to form a translation initiation com-
plex [10]. In the less well-defined rapamycin-insensitive
mTORC2 complex [11], mTOR is associated with the
rapamycin insensitive companion (RICTOR), LST8, mSIN1,
PROCTOR and DEPTOR and phosphorylation of 4E-BP1
on t37/46 is also considered rapamycin insensitive [12]. The
mTORC2 complex is involved in cytoskeletal organisationvia paxillin, rho/rac and PKBα, but it also plays a key role in
cell proliferation and survival via activation of serum and
glucocorticoid protein kinase 1 (SGK1) and direct activation
of Akt [8]. However, the characterisation of mTORC1 and
mTORC2 as rapamycin-sensitive and insensitive complexes
may not always be entirely accurate, as chronic rapamycin
treatment has also been reported to inhibit mTORC2 activ-
ity by blocking its assembly [8,13].
The mTOR inhibitor rapamycin (sirolimus) has been
used clinically as an immunosuppressant drug in trans-
plant medicine [14]. However, it has recently been rea-
lised that the increased activity of the mTOR pathway
caused by upstream changes in regulators, such as
phosphatidylinositol-3 (PI3)-phosphatase (PTEN) and
PI3K, also makes mTORC1 an attractive anti-cancer tar-
get [15] and a number of rapamycin analogues (rapalo-
gues) have been produced: RAD001 (everolimus, Afinitor®,
Novartis), CCI-779 (temsirolimus, Wyeth) and AP23573
(MK-8669) (ridaforolimus ARIAD and Merck pharmaceu-
ticals). The first clinical cancer trials in metastatic breast
cancer with temsirolimus as a monotherapy resulted in
only partial responses [16,17]. The unexpectedly modest
outcomes, with patients acquiring resistance or exhibiting
intrinsic resistance to these allosteric mTORC1 inhibitors,
may be associated with a paradoxical increase in the acti-
vation of Akt and PI3K caused by inhibition of a negative
feedback loop from S6 kinase to IRS-1 in response to
mTORC1 inhibition by rapalogues [18-21], with the sub-
sequent enhanced Akt activation reportedly being associ-
ated with rapalogue monotherapy failure in some patients
[22-24].
However, while monotherapy studies with several signal
transduction inhibitors, including rapalogues, have shown
only modest success in advanced breast cancers, preclinical
data indicate that a combination of anti-hormone and sig-
nal transduction inhibitors (STI's) can provide significantly
greater inhibition than either agent alone [21]. Although
breast cancers may become resistant to first-line anti-
hormone treatment they often retain an active ER and will
still respond to an alternative endocrine agent as a second-
line therapy, but longer-term success is more likely to be
achieved by also targeting up-regulated growth factor path-
ways that can be independent from, or interactive with, ER
signalling pathways. Pre-clinical data were supportive of the
use of current mTOR antagonists alongside endocrine ther-
apy in breast cancer which resulted in a number of clinical
trials using such combination therapies [25]. One of the
earliest phase 3 trials combined letrozole and temsirolimus
and was used on advanced breast cancer but the trial had
to be terminated early due to failure to demonstrate any
benefit [19]. Later studies have been more successful with
very promising results obtained recently in advanced endo-
crine resistant disease where RAD001 (everolimus) was
used in combination with the steroidal aromatase inhibitor
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have shown significant improvement in progression-free
survival from 4.1 months with exemestane alone to
10.6 months with a combination of exemestane and evero-
limus in the BOLERO 2 trial [26] and an improved time to
progression from 4.5 months with tamoxifen alone to
8.6 months with tamoxifen plus everolimus in the TAM-
RAD GINECO trial [27]. These clinical findings indicated
value for the allosteric mTOR inhibitors used alongside
tamoxifen or aromatase inhibitors in advanced endocrine
resistant tumours and there has been recent USA Food and
Drug Administration approval for everolimus in combin-
ation with exemestane in ER+/HER2- metastatic breast
cancer after non-steroidal aromatase inhibitor failure [28].
Nevertheless, there remains a group of patients who
are initially refractory to everolimus/anti-hormone ther-
apy while others relapse at a later point during such
treatment [26,27]. It is feasible that these patients may
gain more benefit from treatment with alternative
mTOR inhibitors that, unlike rapalogues, are not re-
stricted to inhibition of only mTORC1 signalling. It is
thus interesting that several types of new mTOR inhibi-
tors are currently under development. The dual mTOR
and PI3K inhibitors (SF1126-Semafore, NVP-BEZ235-
Novartis, xL765-Exelis-Sanofi and GDC-0980- Roche-
Genentech) simultaneously block both the PI3K and
mTOR signalling and, therefore, have the theoretical ad-
vantage of totally shutting down the PI3K/Akt/mTOR
network [14]. These have the possible drawback of asso-
ciation with greater toxicity but in early small clinical
trials are reported to induce stable disease or partial re-
sponse (see [14]). A new variety of mTOR inhibitors has
also recently emerged which are ATP-competitive inhib-
itors that target the mTOR kinase domain and, thus,
dually-inhibit activity of both mTORC1 and mTORC2
complexes. This approach should be an alternative way
to mitigate the problem of Akt/PI3K activation by nega-
tive feedback seen with rapalogues. Preclinical data for
two such agents, PP242 and PP30, suggest that along
with the additional benefit of mTORC2 inhibition, these
drugs can also be more effective than rapamycin at inhi-
biting mTORC1 activity [14,29,30]. Several pan mTOR
(mTORC1/2) dual kinase inhibitors (AZD8055 and its
related compound AZD2014 (Astra Zeneca), as well as
INK128 (Intellikine) and OSI-027 (OSI Pharmaceuti-
cals)) are currently in phase I/II studies on solid tumours
and breast cancer or lymphoma [30-33]. However, the
value of such dual mTORC1/2 inhibitory strategies re-
mains unknown in the context of endocrine resistance
in breast cancer.
Here, for the first time we show that in comparison
with RAD001, an mTOR kinase inhibitor AZD8055 is
significantly superior as a single agent, modulating both
mTORC1 and mTORC2 signalling, cell growth andsurvival in tamoxifen (TamR) and oestrogen deprivation
(MCF7-X) resistant cell lines that aim to model clinical
relapse following first-line endocrine treatment. Further-
more, we demonstrate that in these endocrine resistant
RAD001-resistant models, AZD8055 results in superior
growth inhibition when used alongside fulvestrant and is
additionally effective alongside anti-hormones during
the earlier, endocrine responsive phase of this disease
in vitro. Cumulatively, these data suggest considerable
potential for mTOR kinase inhibitors that target both
mTORC1 and 2 to subvert resistance during anti-
hormonal management of breast cancer.
Methods
Cell culture
The parental ER + breast cancer cell lineswere fromAmerican
Type Culture Collection (ATCC) (Manassas, Virginia, USA)
(T47D) or a gift from AstraZeneca (MCF-7) Alderly Park,
Macclesfield, (Cheshire, UK). Experimental cells were grown
in phenol red-free RPMI-1640 supplemented with 5% FCS
(foetal calf serum), penicillin/streptomycin (10 U/ml and
10 μg/ml), fungizone (2.5 μg/ml) and 4mMglutamine. All cell
culture reagents and FCSwere from Invitrogen LifeTechnolo-
gies (Fisher Scientific, Loughborough, UK). Cell lines were
used within a window of 20 passages. The acquired ER+
tamoxifen-resistant cell line, TamR, was derived from MCF-7
cells continuously exposed to 10-7 M 4-hydroxytamoxifen
(Sigma-Aldrich, Gillingham, Dorset, UK) until emergence
(from six months) of a cell line resistant to the growth inhibi-
tory properties of this anti-hormone as previously described
[34]. ER + acquired tamoxifen-resistant T47D-tamR cells were
also available for this study, similarly derived by our group
from T47D cells following continuous exposure to 10-7 M 4-
hydroxytamoxifen. Stable TamR cells were routinely main-
tained in phenol-red free RPMI-1640, 5% charcoal-stripped
FCS (sFCS) and 10-7M4-hydroxytamoxifen, withT47D-tamR
cells also maintained in the presence of this anti-hormone.
The ER+model used for acquired resistance to severe
oestrogen deprivationwasMCF7-X, derived fromMCF-7 cells
grown in phenol-red free RPMI containing 5%heat inactivated
(65°C, 40 minutes) charcoal stripped FCS (X medium) as de-
scribed previously [3]. Two ER negative acquired ful-
vestrant (Faslodex)-resistant cell lines were also available
for study generated from MCF-7 (FasR) and T47D (T47D-
fasR) cells continuously exposed to fulvestrant (10-7 M) for
>2 years as previously described [35].
Growth curves
Cells were seeded overnight at 40,000 cells/well (24-
well plate) in their respective growth media. Cells were
grown for seven days with 1 nM to 1,000 nM of the
mTOR inhibitors AZD8055 or RAD001 (gifts from
AstraZeneca) or appropriate vehicle control (dimethyl
sulphoxide (DMSO)). Cell growth was evaluated by
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was measured using a Coulter Counter. All TamR,
MCF-7, MCF7-X, T47D-tamR and T47D-fasR experi-
ments were performed at least in triplicate. In com-
bination studies, fulvestrant was routinely used at 100
nM, a concentration shown previously to be growth
inhibitory in TamR and MCF7-X models [2,3]. The
growth impact of AZD8055 (0 to 100 nM) alongside
oestrogen deprivation (using X cell medium as de-
scribed above) or 10-7 M 4-OH tamoxifen was also
evaluated in MCF-7 cells.Western blotting
Cell lines were grown to 70% confluence in their
respective media and then treated with a concentration
range (1 nM to 100 nM) of AZD8055 or RAD001 for
15 minutes to 24 hours. Monolayers were washed with
PBS and lysed in ice-cold lysis buffer (50 mM TRIS,
5 mM ethylenediaminetetraacetic acid (EDTA), 150 mM
NaCl, 1% Triton-X100 pH 7.5) supplemented with pro-
tease and phosphatase inhibitors as previously described
[4]. Lysates were clarified by centrifugation (12,000 rpm,
15 minutes, 4°C) and the protein concentration of the
supernatant was determined. A total of 20 μg protein
was boiled for five minutes in SDS/dithiothreitol (DTT)
sample buffer and resolved by SDS-PAGE. Proteins were
transferred to nitrocellulose and after blocking for one
hour in 5% skimmed milk (10 mM TRIS, 150 mM NaCl,
0.05% Tween 20 pH 7.6), they were incubated overnight
with primary antibodies (1:1,000 dilution): mTOR (Cell
Signalling Technology, Boston, Massachusetts, USA #2972);
P (ser2481) mTOR (Cell Signalling #2974); P(ser 2448)mTOR
(Cell Signalling #2971); Akt (Cell Signalling #9272); P (ser 473)
Akt (Cell Signalling #9271); p70S6k (Cell Signalling #9202);
P(thr389)-p70S6k (Cell Signalling #9205); S6 ribosomal protein
(Cell Signalling #2217); P (ser235/236)-S6ribosomal protein
(Cell Signalling #2211); 4EBP-1 (Cell Signalling #9644);
P (thr37/46)4E-BP-1 (Cell Signalling #2855); P (thr246) PRAS40
(Cell Signalling #2997); PRAS40 (Cell Signalling #2610);
P-(thr202/tyr402) erk42/44 (Cell Signalling #9101); p44/42
MAPK/erk1/2 (Cell Signalling #9102); ERα (Santa Cruz
Biotechnology, Dallas, Texas, USA sc543); P (ser167)ER
(Upstate Merck Millipore, Billerica, Massachusetts, USA
#07-481); and P (ser118) ER (Santa Cruz 12915). Actin
(Sigma # A5441, at 1:50,000) was used as a loading
control. Blots were washed with TBS/Tween and bound
antibodies were detected after one hour incubation with
horseradish peroxidase (HRP)-labelled secondary antibodies
(1:10,000). Bound proteins were visualised by enhanced
chemiluminescence (Pierce, Thermoscientific, Rockford,
USA). Where appropriate, signal quantification was per-
formed by densitometry (AlphaEase system) and normal-
ised relative to actin.Polymerase Chain Reaction
Total RNA was extracted from monolayers of cells
treated for 72 hours with 0 to 100 nM AZD8055 using
TRIzol (Sigma) according to the manufacturer’s instruc-
tions. Reverse transcription was performed on 1 μg total
RNA and PCR was performed as previously described [4].
Oligonucleotide primers were synthesised by Invitrogen
and co-amplification was performed with β-actin used as a
loading control. Samples treated with oestradiol or fulves-
trant were used as a positive control to show ER-regulated
modulation of target genes in MCF7-X and TamR cells
[3,36]. PCR products were quantified by densitometry
(AlphaEase) and normalised relative to actin. The follow-
ing primers were used in this study:
ß-Actin – GGA GCA ATG ATC TTG ATC T and
CCT TCC TGG GCA TGG AGT CCT (202 bp)
Amphiregulin - TCC TCG GGA GCC GAC TAT GAC
and GGA CTT TTC CCC ACA CCG (330 bp)
pS2 - CAT GGA GAA CAA GGT GAT CTG and
CAG AAG CGT GTC TGA GGT GTC (336 bp)
cyclin D1-GCC TGT GAT GCT GGG CAC TTC ATC
TG and TTT GGT TCG GCA GCT TGC TAG GTG
AC (358 bp)
c-myc- TTG CAG CTG CTA GAC GCT G and CCA
CAT ACA GTC CTG GAT GA (470 bp)
bcl2- CAC CTG TGG TCC ACC TGA C and AGC
CAG GAG AAA TCA AAC AGA G (376 bp)
Immunocytochemistry
Subconfluent monolayers of TamR or MCF7-X cells
were treated for one hour (phospho-ERα) or 72 hours
(Ki67, ERα, pS2) in their respective growth media
in the presence of AZD8055 (1 to 100 nM) on 3-
aminopropyltriethoxysilane coated glass coverslips. Stain-
ing for the proliferation marker Ki67 (MIB1 antibody) was
performed on cells fixed in 3.7% formaldehyde/0.15 M
NaCl for ten minutes, five minutes in 100% ethanol with a
final wash in PBS before assay. Staining for phosphory-
lated ERα (ser167 or ser118 sites), pS2 and total ERα was
performed on cells optimally-fixed for fifteen minutes with
3.7% formaldehyde in PBS, five minutes PBS, five minutes
methanol (−20°C), five minutes acetone (−20°C) and five
minutes PBS or with 2% paraformaldehyde with 20 mM
orthovanadate for twenty minutes followed by 2 x five mi-
nutes PBS washes (ERα 118). Coverslips were blocked
with PBS/0.02%Tween for five minutes and incubated
with 1:150 MIB1 (M7074 Dako Ltd, Ely, Cambridgeshire,
UK) in PBS for one hour, or with 1:175 ERα (AB ER clone
6 F11 Vector Laboratories, Peterborough, UK) for 90 -
minutes; 1:100 ERα 167 (Upstate #07-481); 1:400 pS2
(Novocastra, Leica Biosystems, Newcastle-upon-Tyne,
UK) for 90 minutes or 1:25 ERα 118 (Cell Signalling #
2515) overnight at room temperature. Unbound antibody
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system was used for visualization (one to two hours at
room temperature). Coverslips were washed in PBS and
detected with diaminobenzidine tetrahydrochloride (DAB)
and hydrogen peroxide chromogen substrate (Dako) and
counterstained with methyl green. Immunostaining was
evaluated at 20× magnification using an Olympus BH-2
light microscope and representative photographs were
taken. For Ki67, estimates of percentage of cells deemed
positive versus negative/equivocally-stained were deter-
mined from five fields of view for each coverslip (20x
magnification) from three independent experiments.Sytox green viability assay
A Sytox green viability assay was modified from Jones and
Singer [37]. Cells were seeded into 96-cell plates (5,000
cells/well) and left to adhere overnight (37°C, 5% CO2).
After 24 hours (day 0), Sytox green, a cell impermeant
green-fluorescent nucleic acid stain (Invitrogen), was
added to each control well (n = 8) (final concentration
1:25,000) and after one hour the number of cells with a
compromised plasma membrane (that is, late apoptotic
and necrotic cells) that had taken up the sytox green was
counted (number/well) using a fluorescent microscope.
Cell membranes were permeabilised overnight with 0.25%
saponin (Sigma) in the presence of sytox green, and then
total cell number/well was counted. The remaining experi-
mental cells were cultured for 72 hours in the presence of
AZD8055 (0 to 100 nM), then the sytox green assay was
performed to give a count for dead and total cell numbers
as described above. Data were subsequently analysed by
comparing live cell counts on day 0 with live cell counts
on day 3. Cell death was considered to have occurred
when the viable cell number fell below the day 0 pre-
treatment control number. Each treatment was assessed
from eight replicates and three independent experiments.Migration assay
Pore inserts (8 μm, Costar #3422) were incubated with
300 μl sterile fibronectin (Sigma) in PBS (10 μg/ml) for two
hours at 37°C. Excess fibronectin was removed from the bot-
tom of the insert by washing in PBS. Inserts were air dried
for 15 minutes, then 650 μl cell culture medium +/− 25 nM
AZD8055 was placed in the well and the insert suspended in
it. A total of 40,000 TamR cells in normal growth medium
were added to the insert and the plate was incubated for
24 hours at 37°C. Cells on the insert were fixed with 3.7%
formaldehyde (15 minutes). Cells on the inside of the insert
were removed with a cotton swab and cells that had mi-
grated to the lower side of the insert membrane were stained
with 0.5% crystal violet for 30 minutes. Excess stain was
removed by repeated washing with distilled water. Migrated
cells were counted under an inverted light microscope overfive fields of view (x20). Each experiment included triplicate
wells and the experiment was repeated twice.Statistics
Statistical analyses were carried out using a two sided
t-test and ANOVA with post hoc test. P <0.05 was
considered significant.Results
Differential effects of RAD001 and AZD8055 on proliferation
and signalling in acquired endocrine- resistant models
The allosteric mTOR inhibitor RAD001 (everolimus) was a
relatively poor inhibitor of growth measured over seven
days in MCF7-derived tamoxifen-resistant cells (TamR)
with an IC50 of 950 nM. In long-term oestrogen deprived
(MCF7-X) resistant MCF-7 cells, RAD001 was found to be
even less potent (P <0.05) with an IC50 >1 μM (Figure 1A).
In contrast, the mTOR kinase inhibitor AZD8055 at 10 to
100 nM was a very effective inhibitor of growth in TamR
cells (P <0.001) with an IC50 of 18 nM. AZD8055 10 to 100
nM also substantially (P <0.001) inhibited growth of the
MCF7-X cell model, with an IC50 of 24 nM (Figure 1B),
although MCF7-X cells were significantly less sensitive than
the TamR cells to AZD8055 when examined at 25 nM (P =
0.035) and 50 nM (P =0.019). Additional studies performed
in a tamoxifen-resistant T47D-derived model (T47D-tamR)
further confirmed that AZD8055 was highly growth inhibitory
(IC50 19 nM) in acquired endocrine-resistant cells (Figure 1C).
Despite having a poorer effect on cell growth, one
hour treatment with RAD001 was still shown to inhibit
mTORC1 (rapamycin sensitive) associated signalling
pathways with TamR cells being slightly more sensitive
to RAD001 than MCF7-X cells (Figure 1D). In both cell
lines, RAD001 at 100 nM caused a reduction in mTOR
phosphorylation at s2448, which has previously been
described as the site predominantly associated with the
mTORC1 complex [38]. Downstream p70S6K phos-
phorylation in TamR was undetectable after treatment
with 1 nM RAD001 and pS6 activity was inhibited with
RAD001 >10 nM. These mTORC1 downstream pathways
were less sensitive to RAD001 in MCF7-X cells, but phos-
phorylation of p70S6K and pS6 were still inhibited by
100 nM RAD001. However, in both models, there was
no impact of one hour treatment with RAD001 on
pPRAS40. RAD001 was a poor inhibitor of mTORC2
(predominantly rapamycin-insensitive) pathways in both
TamR and MCF7-X cells, indicated by its failure to signifi-
cantly reduce both s473 Akt phosphorylation and mTOR
phosphorylation at s2481, a site known to be associated
with mTORC2 [38]. In both TamR and MCF7-X cells,
RAD001 also failed to inhibit 4EBP-1 phosphorylation on
the t37/46 site which has previously been described as
rapamycin-insensitive [12].
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Figure 1 Comparison of RAD001 and AZD8055 effect on cell growth and mTORC1/2 signalling pathways in TamR and MCF7-X cells.
TamR (black squares) and MCF7-X cells (white squares) were grown for seven days in the presence of RAD001 (0 to 1,000 nM) (A) or AZD8055 (B) (0 to 100
nM) and cell number determined by Coulter Counting. The effect of AZD8055 on seven days growth of tamoxifen-resistant T47D-tamR cells similarly
determined is shown in (C). Results expressed as% control are the mean (+/− SEM) of three to five independent experiments. *P <0.05 versus appropriate
cell line control (0), **P <0.01 versus appropriate cell line control (0), ***P <0.001 versus appropriate cell line control (0). Western blot of 70% confluent TamR
and MCF7-X cells treated for one hour with RAD001 or AZD8055 (0 to 100 nM) (D). Blots were probed with phospho- and total antibodies for mTORC1
(rapamycin sensitive) and mTORC2 (rapamycin insensitive) signalling pathways. Blot shown is representative of at least two independent experiments.
Jordan et al. Breast Cancer Research 2014, 16:R12 Page 6 of 17
http://breast-cancer-research.com/content/16/1/R12In contrast to RAD001, one hour treatment with
AZD8055 inhibited pathways associated with both
mTORC1 and mTORC2 signalling in both TamR and
MCF7-X endocrine-resistant cell lines (Figure 1D). At con-
centrations from 1 to 100 nM, the inhibition of mTORC1
pathway elements, p-p70s6kinase and p-S6 ribosomal
protein was similar or superior with AZD8055 to that seen
with RAD0001. While inhibition of p-PRAS40 was not
detected after one hour treatment with RAD001, PRAS40
phosphorylation was eliminated by 100 nM AZD8055 in both
TamR and MCF7-X cells. The biggest difference was seen
with the mTORC2 associated signalling caused by AZD8055
with reduced activation of s2481 p-mTOR, complete inhib-
ition of p-Akt by AZD8055 at 1 to 10 nM and at concen-trations >10 nM complete inhibition of 4EBP-1 at the
rapamycin insensitive site t37/46. There was no consistent
effect across replicate preparations on total protein expression
over one hour treatment with either RAD001 or AZD8055.AZD8055 effect on mTORC1 and mTORC2 signalling in
TamR and MCF7-X cells is rapid and sustained
Since superior growth blockade and mTORC1/mTORC2
signalling inhibition was induced by AZD8055 in the
endocrine resistant cancer cells, our subsequent detailed
studies focused entirely on AZD8055. We investigated
the sustainability of the AZD8055 signalling response
and the inhibitory impact of AZD8055 on cell
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http://breast-cancer-research.com/content/16/1/R12proliferation and survival in the TamR and MCF7-X
resistant models.
Initial studies showed that within one hour AZD8055
(10 to 100 nM) inhibited both mTORC1 and mTORC2
signalling pathways similarly in both TamR and MCF7-X
cells. Further studies were performed over a time course
from 15 minutes through to 24 hours. Western blotting
showed that mTORC1 and mTORC2 signalling in TamR
and MCF7-X cells were both extremely sensitive to
AZD8055 with 30 minutes treatment with 50 nM
AZD8055 demonstrating strong inhibition of mTOR at
sites s2448 and s2481 in both resistant cells (Figure
2A-B). AZD8055 at a concentration of 10 nM com-
pletely inhibited phosphorylation of Akt (s473), p70s6K
(t389) and PRAS40 (t246) within 15 minutes. Reductionactin
T-mTOR
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Figure 2 Time course of AZD8055 effect on mTORC1 and TORC2 sign
confluent TamR (A) and MCF7-X (B) cells treated for 15 minutes to 24 hou
total antibodies for mTORC1 and two signalling pathways. In both cell line
AZD8055. Blots shown are representative of at least two independent expe
treated for 15 minutes to 48 hours with AZD8055 (0 to 100 nM) probed wi
shown are from representative experiments.of phosphorylation of pS6 (s235/236) and 4EBP-1 (t37/
46) was slightly slower, with complete inhibition being
detected in TamR cells after 30 minutes of AZD8055
treatment, although p4EBP-1 was slightly less sensitive
to inhibition in MCF7-X cells. The inhibitory effects of
AZD8055 at 100 nM were generally sustained through-
out the time course, with the exception of p4EBP-1 and
p-mTOR (s2448) in MCF7-X cells, although by 24 hours
some recovery of signalling pathways (where expression
returned to basal levels) was seen at the lower concen-
trations of AZD8055 examined. As expected, following
15 minutes to 48 hours treatment, we also observed that
AZD8055 (10 to 100 nM) did not modulate the activa-
tion of p-erk1/2 in both TamR and MCF7-X cells
(Figure 2C).1h
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A B
*
0
10
20
30
40
50
60
0 25 50 100%
 T
am
R
 
w
ith
-v
e 
M
IB
1 
st
ai
n
in
g 
AZD8055 (nM)
0
10
20
30
40
50
60
0 25 50 100
%
 M
CF
7-
X 
w
ith
 -v
e 
M
IB
1 
st
ai
n
in
g
AZD8055 (nM)
*
*
0
50
100
150
200
250
300
0 0 10 25 50 100
day 0 day 3 AZD8055 (nM)
ce
ll 
n
u
m
be
r (
% 
da
y 
0 
co
nt
ro
l)
MCF7-X
TamR
*
*
*
*
*
C
Figure 3 Effect of AZD8055 on proliferation and viability in TamR and MCF7-X cells. Immunocytochemical evaluation of MIB1 proliferation
marker (Ki67) in TamR (A) and MCF7-X cells (B) treated for three days with AZD8055 (0 to 100 nM). Multiple fields of view (x20) were assessed for
% cells expressing no/equivocal MIB1 staining. Results are from three independent experiments. * P <0.05 versus untreated control (ANOVA with
post-hoc test). Sytox green impermeable nuclear stain was used to measure live cell count in TamR and MCF7-X cells in a viability cell assay before
and after three days treatment with AZD8066 (C). After three days in the presence of 25 nM AZD8055, TamR live cell number fell below the
pre-treatment count indicating some cell death with this agent. Live cell count (total minus dead cells) was a mean of eight replicates in three
independent experiments. *P <0.05, ***P <0.001 for three days treatment with AZD8055 versus appropriate day 0 control ANOVA with post-hoc test.
ANOVA, analysis of variance.
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survival and migratory behaviour
The impact of AZD8055 on TamR and MCF-7-X cell
proliferation was monitored using MIB1 Ki67 staining.
Three days treatment with 50 nM AZD8055 reduced
Ki67 staining in both TamR and MCF7-X cells and after
treatment with 100 nM 40% to 50% of all cells were
deemed negative for MIB1 indicating a significant (P <0.05)
exit from the cell cycle (Figure 3A-B). These MIB1
results indicated that the dual mTORC1/2 inhibitor
AZD8055 was acting to partially inhibit cell proliferation
in TamR and MCF7-X cells. It was investigated whether
cell death also contributed to reduced cell numbers in the
presence of a concentration range of AZD8055. The sytox
green viability assay showed that in TamR cells AZD8055
was not only cytostatic, but at concentrations >25 nM,
AZD8055 induced significant cell death with the TamR
viable cell number falling to approximately 50% below
the initial seeding number (P <0.05). In contrast, in
MCF7-X cells there was evidence from sytox greenassays that while an anti-proliferative effect occurred
this was without any significant cell death with
AZD8055 when used as a single agent (Figure 3C).
TamR cells (but not MCF7-X) have increased migratory
ability compared to parental MCF-7 cells [39]. Al-
though numbers of migrated TAMR cells were very
modest, following 24 hours treatment with AZD8055
TamR migration was shown to be reduced by 40%
showing that dual mTORC1/2 blockade has the cap-
acity to impact on both resistant tumour cell growth
and aggressiveness (Figure 4).
Investigation of any cross talk between ER and mTOR
signalling targeted by AZD8055 in TamR and MCF7-X cells
Both TamR and MCF7-X cells were derived from
oestrogen-dependent MCF-7 breast cancer cells that
have acquired tamoxifen or oestrogen deprivation resist-
ance, respectively, but still grow in an ERα dependent
manner [40]. In the TamR cell line, it is already known
that there is prominent cross-talk between erk1/2 and
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Figure 4 Effect of AZD8055 on migration in TamR cells. Twenty-four
hours migration was measured over an 8 μm pore membrane coated
with fibronectin in the presence or absence of 25 nM AZD8055. Results
shown are from a representative experiment (n = 2).
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http://breast-cancer-research.com/content/16/1/R12phosphorylation of the ER s118 site in the ER AF-1
domain [36]. In MCF7-X cells, MAPK and PI3K/Akt
also have the capacity to cross-talk with ER at pERser118
and pERser167, respectively [3]. Activation at such ER
sites by cross-talk can contribute to driving transcription
of oestrogen/ER regulated genes, notably amphiregulin
which plays a part in the growth of TamR cells [36,41]
and also pS2 expression in MCF-7X cells [3]. The pos-
sible contribution of cross-talk between mTOR signal-
ling and ER in these models of tamoxifen or oestrogen
deprivation resistance was thus investigated using
AZD8055 in the current study. Western blotting of
MCF7-X and TamR confirmed prominent basal ER
phosphorylation levels at ser118 and 167 in the latter
model. Both models treated for one hour with AZD8055
(0 to 100 nM) showed, in conjunction with downregula-
tion of mTOR activity at s2448 and s2481, a concentra-
tion dependent inhibition of ER phosphorylation at s167
(Figure 5A). Total ER and phosphorylation of ER at s118
were not significantly affected by AZD8055. Parallel im-
munocytochemistry (ICC) confirmed that nuclear pERser167,
but not pERser118, in both MCF7-X and TamR cells was re-
duced after one hour exposure to 100 nM AZD8055
(Figure 5B).
Potential interplay between mTOR blockade using
AZD8055 and ER signalling was further investigated by
PCR examination of the ER regulated gene pS2 as well
as several ER-regulated genes more closely related tobreast cancer cell growth: amphiregulin (important in
TamR cells; [36], bcl2 (expressed in MCF7-X only), c-
myc and cyclinD1. mRNA expression of these ER regu-
lated genes was measured after 72 hours treatment with
a concentration range of AZD8055 (1 to 100 nM) but
failed to show any significant altered gene transcription
in TamR or MCF7-X cells (Figure 6A-B). ICC in TamR
and MCF7-X cells confirmed that 72 hours treatment
with 1 to 100 nM AZD8055 caused a concentration
dependent reduction in cell number but did not alter
expression of pS2 or ER protein in TamR or MCF7-X
cells (Figure 6C). While only examining a limited panel
of ER-regulated genes, these data do suggest that the
mTOR inhibitor impact was independent of changes in
ER-regulated transcriptional events and, hence, that
mTOR and ER signalling are unlikely to be closely inter-
active in these acquired resistant models. The capacity
for ER independent impact of AZD8055 was further
supported by the demonstration that 25 nM AZD8055
also inhibited growth by 60% (IC50 20 nM) in an ER nega-
tive acquired fulvestrant-resistant cell line derived from
MCF7 cells (FasR) (Figure 7A). This observation was also
supported by AZD8055 growth studies in a T47D-derived
ER- acquired fulvestrant-resistant line (T47D-fasR) with
an IC50 of 18 nM (Figure 7B).
AZD8055 and fulvestrant in combination enhance growth
inhibition in TamR and MCF7-X cells
When ER positive breast tumours acquire resistance to
an anti-hormone, an alternative anti-endocrine therapy
can often be used successfully second-line, although
resistance invariably emerges. In keeping with this, we
have previously shown that the pure anti-oestrogen
fulvestrant is growth-inhibitory in TamR [2] or MCF7-X
cells in vitro [3], but growth inhibition is only partial,
with the cells subsequently acquiring resistance to ful-
vestrant. We have investigated whether co-treating with
a further anti-hormonal measure (fulvestrant) alongside
an mTOR kinase inhibitor could offer an improved
second-line treatment for endocrine-resistant cells ver-
sus either strategy alone. This was also important to
evaluate since AZD8055 appears to be inhibitory inde-
pendently of any substantial impact on ER-regulated
events in our acquired endocrine resistant models. When
TamR cells were treated for seven days with 25 nM
AZD8055 in combination with fulvestrant (100 nM) there
was a further 60% decrease in growth above that caused
by fulvestrant (P <0.001) and a 50% enhancement of
growth inhibition compared to AZD8055 alone (P <0.05)
(Figure 8A). A similar improved anti-tumour effect was
also observed in MCF-7X cells co-treated with AZD8055
and fulvestrant (Figure 8B) in which 25 nM AZD8055
caused a further 60% decrease in growth above fulvestrant
(P <0.01) or AZD8055 alone (P <0.05). These results
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Figure 5 (See legend on next page.)
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Figure 5 One hour treatment with AZD8055 affects pERser167 protein expression in TamR and MCF7-X cells. Western blot of 70%
confluent TamR and MCF7-X cells treated for one hour with AZD8055 (25 to 100 nM). Images show blots probed for pER (s118 and s167), total
ER, mTOR phosphorylation on s2481 and s2448 to demonstrate mTOR inhibition and actin to indicate equal loading. The accompanying bar
charts show densitometric analysis of western blot data normalised to actin. pERser167 but not pERser118 protein was inhibited in MCF7-X and TamR
cells. Blots are representative of two independent experiments (A). Accompanying immunocytochemical images confirm the effect of AZD8055
on pERser167 but not pERser118 protein expression in TamR and MCF7-X cells. Immunocytochemistry was performed on TamR and MCF7-X cells
fixed after treatment +/− AZD8055 (100 nM) for one hour and cells were stained with antibodies for pERser118 and pERser167 (B). At least five fields
of view were examined for staining and representative images (x20) shown. Results are shown from at least three independent experiments.
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http://breast-cancer-research.com/content/16/1/R12suggest that an mTOR kinase inhibitor (exemplified here
by AZD8055) plus anti-oestrogen fulvestrant combination
could have potential as a superior second-line treatment
for endocrine resistant breast cancers that do not respond
well to the rapalogue everolimus.
Finally, while seven day treatment with AZD8055 was
also a good inhibitor of growth in anti-oestrogen sensitive
MCF-7 parental cells with an IC50 of 12 nM (Figure 9), a
superior growth inhibition could again be obtained by
co-treatment with AZD8055 and either 4-OH-tamoxifen
(10-7 M) or severe oestrogen deprivation (X medium
containing charcoal stripped and heat treated FCS).
The anti-tumour effect was increased by 66% (P <0.01)β-actin
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Figure 6 AZD8055 does not significantly affect ER regulated gene exp
(A) and TamR (B) after 72 hours treatment with AZD8055 (0 to 100 nM) and g
ethidium bromide stained 2% agarose gel with the upper band showing cycl
expressed in TamR) and the β-actin PCR product (lower band). The bar charts
significantly affected by AZD8055. Data are representative of two independen
72 hours treatment with a concentration range of AZD8055 (0 to 100 nM) do
TamR cells (C). Images shown (x20) are representative of three independent eand 56% (P <0.05), respectively, by combination with 10
nM AZD8055 versus the anti-hormone treatment alone
(Figure 9). These findings suggest that in combination
with anti-hormone therapy, mTOR kinase blockade could
also provide a first-line treatment strategy to inhibit endo-
crine responsive disease more effectively and thereby
hinder acquisition of resistance in breast cancer.
Discussion
Endocrine resistant breast cancer and clinical status of
mTOR targeting with rapalogue RAD001
Acquisition of resistance to endocrine therapy remains a
major problem in the treatment of ER + breast cancer5 TamR MCF7-XMCF7-X
ER PS2
TamR
ression in MCF7-X and TamR cells. RNA was extracted from MCF7-X
ene expression analysed by semi-quantitative PCR. The image shows an
in D1, pS2 c-myc, bcl2 (only expressed in MCF7-X) and amphiregulin (only
show actin-normalised values for the ER regulated genes which are not
t experiments. Accompanying immunocytochemical images confirm that
es not significantly affect pS2 or total ER protein expression in MCF7-X or
xperiments.
020
40
60
80
100
120
0 10 25 50 100
Ce
ll 
n
u
m
be
r (
% 
co
n
tr
ol
)
AZD8055 (nM)
T47D-fasR
*
*
*
*
*
*
*
*
*
*
*
0
20
40
60
80
100
120
0 1 10 25 50 100
ce
ll 
n
u
m
be
r (
% 
co
n
tr
ol
)
AZD8055 (nM)
MCF7-FasR
*
*
*
*
*
*
A
B
Figure 7 AZD8055 effect on growth of ER- acquired fulvestrant-
resistant MCF7 (FasR) and T47D cells (T47D-fasR). FasR (A) and
T47D-fasR (B) cells were grown for seven days in the presence of
AZD8055 (0 to 100 nM) and cell number determined by Coulter
counting. Results expressed as% control. **P <0.01, ***P <0. 001.
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Figure 8 Greater inhibition of TamR (A) and MCF7-X (B) cell
growth by the pure anti-oestrogen fulvestrant is apparent
when the drug is used in combination with AZD8055. TamR
cells were grown for seven days in the absence of tamoxifen. TamR
and MCF7-X cells were then grown for seven days in the presence
of fulvestrant (10-7 M) and AZD8055 (0 to 25 nM). Cells were
counted and the results expressed as a percentage of the untreated
control. Results are means of four independent experiments. Statis-
tical analyses used ANOVA with a post hoc test to compare doses of
AZD8055 plus fulvestrant versus AZD8055 alone and AZD8055 plus
fulvestrant versus the fulvestrant alone control (0). *P <0.05, **P <0.01,
***P <0. 001. ANOVA, analysis of variance.
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http://breast-cancer-research.com/content/16/1/R12and using inhibitors to target de-regulated growth factor
signalling pathways, such as mTOR, has become an
important therapeutic approach currently under intense
clinical evaluation. Initial preclinical studies demon-
strated that tamoxifen resistance is mediated in part by
mTOR signalling [42]. This contributed towards the
rationale for successful clinical studies where rapalogue
treatment was combined with aromatase inhibitor (BO-
LERO-2) or tamoxifen (TAMRAD) therapy [26,27,43,44]
which resulted in approval of the rapalogue everolimus
(Afinitor, RAD001), in combination with the steroidal aro-
matase inhibitor exemestane (Aromasin), for treatment
of post-menopausal women with advanced ER+/HER2-
breast cancer progressing on a non-steroidal aromatase
inhibitor. Critically, however, although the BOLERO-2
trial showed that the objective response rate was im-
proved for everolimus/antihormone combination versus
antihormone alone, no patients showed complete re-
sponse and some patients remained refractory to this
rapalogue therapy or developed resistance during treat-
ment [26]. The signalling pathways that limit the impact
of rapalogues in endocrine resistant breast cancer have to
date been largely undefined. Here, we have studied the use
of the mTOR kinase inhibitor AZD8055 as a potentialtreatment for acquired endocrine-resistant breast cancers
including those refractory to rapalogue treatment.
Importance of mTORC2/AKT signalling in acquired endocrine
resistant models resistant to rapalogue RAD001
Our study has predominantly focussed on MCF7-X and
TamR cells as in vitro models that aim to represent
clinical relapse after first line oestrogen deprivation or
tamoxifen treatment, respectively [2,3]. Interestingly, we
found that MCF7-X cell growth was completely, and
TamR cells partially, resistant to inhibition by RAD001
(everolimus, IC50 ≥1uM), despite inhibition of target
TORC1 signalling (mTORCser2448, p70S6k and pS6).
Similar growth and signalling effects have been reported
by others in MCF-7 cells with acquired tamoxifen-
resistance [45]. Critically, in our study RAD001 failed
to inhibit the mTORC2 signalling complex which
is a major regulator of Akt activity [46]. Thus, p-
mTORser2481 (mTORC2), p-Aktser473 and also growth,
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Figure 9 Greater inhibition of MCF-7 cell growth is apparent
when AZD8055 is used in combination with tamoxifen or
oestrogen deprivation. Seven days growth of oestrogen
dependent MCF-7 cells was compared in standard control medium
(black squares), in the presence of 10-7 M tamoxifen (grey square) or
oestrogen-deprived medium (X cell medium) (white squares) with a
concentration range of AZD8055 (0 to 100 nM). Triplicate wells of
cells were counted by Coulter Counter and the results expressed as
a percentage of the untreated control cells. Combination with 10
nM AZD8055 significantly increased growth inhibition in the pres-
ence of tamoxifen or oestrogen-deprived medium by 66% and 56%,
respectively, versus anti-hormone alone. *P <0.05, **P <0.01, ***P <0.001
versus appropriate anti-hormone control in the absence of AZD8055 (0).
Results shown are means of three independent experiments. Statistical
analysis was performed with ANOVA and post hoc test. ANOVA, analysis
of variance.
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http://breast-cancer-research.com/content/16/1/R12which is in part AKT-driven in TamR and MCF7-X cells
[3,4], were not inhibited by this agent. Reports of
rapamycin-sensitivity in long-term oestrogen deprived
(LTED) MCF-7 cells from other groups [45,47-50] have
ranged from being modest [48] to very sensitive [49], with
increased HER2 expression invariably reported to be a
predictor for their increased RAD001 sensitivity [45,49].
Oestrogen deprivation-resistant MCF7-X cells differ in
that they do not have up-regulation of HER2 (or IGF1R)
[3], and indeed such growth factor receptors only rarely
increase in clinical endocrine relapse samples [51]. It is
thus probable that some dependence on the PI3K/Akt
pathway in MCF7-X cells coupled with only low HER2
activity cumulatively results in their prominent growth-
insensitivity to RAD001.Rapalogue insensitive acquired endocrine resistant cells
retain sensitivity to mTOR kinase inhibition
Given their substantial RAD001 growth insensitivity, TamR
and MCF7-X cells could comprise useful models to under-
stand everolimus resistance in tamoxifen or oestrogen
deprivation-resistant patients and to determine improved
treatments. In this regard, our findings suggest that inhib-
ition of both TORC2/Akt and TORC1 may be critical. We
have shown that growth of cancer cells unresponsive to an
allosteric mTOR inhibitor can still be sensitive to mTOR
kinase blockade, with AZD8055 substantially inhibitinggrowth in TamR and MCF7-X cells (IC50 18 and 24 nM,
respectively). To the best of our knowledge, this is the first
report suggesting the potential for mTOR kinase inhibitors
in rapalogue-(RAD001) insensitive ER+/HER2- breast can-
cer cells with acquired endocrine resistance. Clearly, it
should be remembered that there are limitations to studies
based on homogeneous cell cultures because such model-
ling cannot reflect the breadth of clinical heterogeneity of
ER + disease or microenvironment impact [52,53]. How-
ever, experimental work has shown that resistant cell lines
can reflect features seen in some clinical breast cancer
samples [54,55] and our additional results here are encour-
aging in that they show AZD8055 is also highly growth-
inhibitory in a further ER + acquired endocrine-resistant
model, T47D-tamR (IC50 19 nM).
Our TamR and MCF7-X signalling studies indicate
that the difference in the mechanism of action of these
drugs enables AZD8055 to target mTORC2 signalling in
addition to mTORC1; thus, basal p-Aktser 473 is rapidly
and substantially inhibited by AZD8055 in both models
but is unaffected by RAD001. Furthermore, inhibition
of a negative feedback loop downstream of mTORC1
[22,24] can result in induction of Akt activity in patients
treated with everolimus [18]. This event may limit the
effectiveness of mTORC1-targeting therapy since it can
be associated with shortened time to progression in pa-
tients [56,57]. However, in both TamR and MCF7-X
cells, basal Akt ser473 inhibition by AZD8055 was sus-
tained with no up-regulation over 24 hours treatment. A
similar response to AZD8055 has been reported in fur-
ther breast cancer cell lines [12], while clinically a close
analogue of AZD8055, AZD2014, also inhibits pAKT,
pS6 and p4EBP-1 in some tumours [58].
AZD8055 has previously been reported to induce cell
death and autophagy in lung and leukaemia cancer cells
[59-61], contrasting rapalogues that are often poor inducers
of cell death [12,59]. In the present study, some cell death
was induced in TamR but not in MCF7-X cells by
AZD8055. Since bcl-2 mRNA was detected basally in
MCF7-X, but not in TamR cells, this anti-apoptotic factor
may contribute towards the somewhat-reduced AZD8055-
sensitivity in MCF7-X versus TamR cells. Interest-
ingly, rapamycin-resistant tumours have previously been
reported to express high levels of bcl-2 [62,63]. The in-
creased effectiveness of AZD8055 over RAD001 in TamR
and MCF7-X cells may also relate to the reported ability
of mTOR kinase inhibitors to deplete overall protein syn-
thesis more strongly than rapamycin [64], where inhibition
of 4E-BP1 phosphorylation at rapamycin resistant sites t37
and 46 [12] with AZD8055 may increase inhibition of
cap-dependent translation [61,65]. Interestingly, AZD8055
showed a superior impact on 4E-BP1 phosphorylation in
TamR versus MCF7-X cells, which may contribute to-
wards increased AZD8055 sensitivity in the former model.
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independently of ER in acquired endocrine resistant cells
Clinically, acquired endocrine-resistant tumours often
respond to second-line antihormonal therapy and TamR
and MCF7-X cells similarly retain ER dependency,
responding to fulvestrant challenge [2,3]. In endocrine-
resistant cancers, nuclear ER activity can be driven in a
ligand-independent manner via cross-talk with growth
factor protein kinase cascades including MAPK and PI3K/
Akt with emerging evidence for a role of mTOR [43].
Thus, rapalogue treatment has been reported to inhibit
pERser167 in LTED MCF-7 cells and in a tamoxifen and
fulvestrant-resistant MCF-7-derived line R-MVLN [49,66],
while S6kinase (S6K), a downstream TORC1 target, is also
able to phosphorylate a consensus motif at pERser167
[67,68]. Although our results have also provided some
support of cross-talk via ER phosphorylation in MCF7-X
and TamR cells, where pERser167 was rapidly inhibited by
the mTOR kinase inhibitor AZD8055, extensive PCR in-
vestigation failed to demonstrate any significant inhibitory
effect of AZD8055 on ER-regulated gene transcription.
We have also been unable to show a convincing impact of
AZD8055 on basal or oestradiol-stimulated oestrogen
response element activity in MCF7-X and TamR using
reporter gene construct studies (data not shown). The
contribution of ER phosphorylation at individual sites is
generally underexplored, although phosphorylation of ei-
ther ser167 or ser118 in the AF1 domain of ERα can exert
only a small effect on gene transcription [69]; hence, the
significance of ERser167 inhibition with AZD8055 in TamR
and MCF7-X cells remains unclear. Significantly, in TamR
cells, EGFR/MAPK signalling is a predominant driver of
pERser118 [36] and MAPK also has some capacity in main-
taining pERser118 activity in MCF7-X cells [3]. The obser-
vation that activity of both pERser118 and MAPK were
refractory to AZD8055 may thus explain the apparent
inability of the drug to impact on genomic ER function in
these endocrine-resistant cells. Clearly, AZD8055 appears
able to promote its growth inhibitory effects in an ER inde-
pendent manner in TamR and MCF7-X cells, an outcome
supported by the observation that it retains substantial
growth-inhibitory activity in two acquired fulvestrant-
resistant cell lines that have lost all ER expression
(MCF-7-derived FasR and also T47D-fasR) [35]. Interest-
ingly, rapalogues have also been shown to have favourable
activity in triple-negative breast cancer cells [70].Superior impact of mTOR kinase inhibitor alongside
further ER blockade (fulvestrant) in acquired endocrine
resistant models
We have previously shown that although ER remains an
important growth contributor in TamR and MCF7-X cells,
fulvestrant responses are incomplete in these models andresistance subsequently emerges during treatment [2,3,36].
This finding mirrors relapse during second line endocrine
treatment that occurs in many patients. Reports in various
cell lines have shown that co-treatment with everolimus and
endocrine therapy can exert additive or synergistic growth
inhibitory effects [42,43,71,72]. Importantly, AZD8055 sig-
nificantly improved the anti-tumour effect of fulvestrant in
bothTamR and MCF7-X cells, suggesting that such combin-
ation treatment might prove valuable in breast cancer after
initial endocrine failure. Moreover, since our TamR and
MCF7-X models were also RAD001 refractory, it is feasible
that the value of such combination therapy might extend to
patients who are refractory to combined treatment with
everolimus plus exemestane or tamoxifen [26,27]. Our pre-
clinical findings are promising given that trials are ongoing
in advanced breast cancer patients using fulvestrant in com-
bination with the mTOR kinase inhibitor AZD2014
(ClinicalTrials.gov: NCT01597388). Finally, it is note-
worthy that in the parental MCF-7 line, we also observed
a greater anti-tumour effect with AZD8055 alongside tam-
oxifen or oestrogen-deprivation. As such, co-treatment
may additionally have some capacity to hinder develop-
ment of resistance. The efficacy of everolimus alongside
endocrine agents in the adjuvant setting is currently being
explored in ER+/HER2- patients at high risk of relapse
(ClinicalTrials.gov: UNIRAD), and based on our pre-
clinical findings here, evaluation of early combination
treatment using an mTOR kinase inhibitor may be equally
worthy of exploration where it may help to delay or
prevent acquisition of endocrine resistance.Conclusions
Our findings using endocrine-resistant breast cancer cell
lines demonstrate for the first time that dual targeting of
mTORC1 and mTORC2/AKT signalling with an mTOR
kinase inhibitor (AZD8055) can be effective even under
conditions in which the allosteric mTORC1 inhibitor
RAD001 (everolimus) fails to control growth. Moreover,
combined treatment with AZD8055 alongside anti-
hormones provides a particularly potent growth inhibi-
tory strategy both for the TamR and MCF7-X models
and for endocrine responsive MCF-7 cells.Abbreviations
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